Truist lifts Cano Health Inc. [CANO] price estimate. Who else is bullish?

Cano Health Inc. [NYSE: CANO] closed the trading session at $8.74 on 09/26/22. The day’s price range saw the stock hit a low of $8.46, while the highest price level was $9.05. The company report on September 12, 2022 that Cano Health to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Cano Health Inc. (“Cano” or the “Company”) (NYSE: CANO), a leading value-based primary care provider and population health company, today announced it will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Dr. Marlow Hernandez, Chairman and Chief Executive Officer, and Brian Koppy, Chief Financial Officer, will participate in a fireside chat at 4:05 p.m., Eastern Time.

A live webcast will be accessible through Cano Health’s Investor Relations website at investors.canohealth.com. The webcast will be archived for replay following the conference.

The stocks have a year to date performance of -1.91 percent and weekly performance of 33.64 percent. The stock has been moved at 34.46 percent over the last six months. The stock has performed 22.41 percent around the most recent 30 days and changed 80.95 percent over the most recent 3-months.

If compared to the average trading volume of 4.78M shares, CANO reached to a volume of 7077291 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Cano Health Inc. [CANO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CANO shares is $9.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CANO stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Truist have made an estimate for Cano Health Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on September 07, 2022. While these analysts kept the previous recommendation, Raymond James raised their target price to Outperform. The new note on the price target was released on June 24, 2022, representing the official price target for Cano Health Inc. stock. Previously, the target price had yet another drop from $8 to $6, while BofA Securities kept a Neutral rating on CANO stock.

The Average True Range (ATR) for Cano Health Inc. is set at 0.73, with the Price to Sales ratio for CANO stock in the period of the last 12 months amounting to 1.71. The Price to Book ratio for the last quarter was 4.46, with the Price to Cash per share for the same quarter was set at 0.10.

CANO stock trade performance evaluation

Cano Health Inc. [CANO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.64. With this latest performance, CANO shares gained by 22.41% in over the last four-week period, additionally plugging by 34.46% over the last 6 months – not to mention a drop of -37.84% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CANO stock in for the last two-week period is set at 70.65, with the RSI for the last a single of trading hit 75.33, and the three-weeks RSI is set at 67.11 for Cano Health Inc. [CANO]. The present Moving Average for the last 50 days of trading for this stock 6.24, while it was recorded at 7.72 for the last single week of trading, and 6.14 for the last 200 days.

Cano Health Inc. [CANO]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Cano Health Inc. [CANO] shares currently have an operating margin of -5.89 and a Gross Margin at +9.29. Cano Health Inc.’s Net Margin is presently recorded at -1.12.

Return on Equity for this stock declined to -4.03, with Return on Assets sitting at -1.27.

Cano Health Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 2.00.

Cano Health Inc. [CANO]: Insider Ownership positions

There are presently around $1,452 million, or 73.50% of CANO stock, in the hands of institutional investors. The top three institutional holders of CANO stocks are: FMR LLC with ownership of 31,162,099, which is approximately 3.826% of the company’s market cap and around 18.30% of the total institutional ownership; JPMORGAN CHASE & CO, holding 16,160,541 shares of the stock with an approximate value of $141.24 million in CANO stocks shares; and VANGUARD GROUP INC, currently with $138.4 million in CANO stock with ownership of nearly 24.397% of the company’s market capitalization.

Positions in Cano Health Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 78 institutional holders increased their position in Cano Health Inc. [NYSE:CANO] by around 41,466,695 shares. Additionally, 80 investors decreased positions by around 30,259,012 shares, while 22 investors held positions by with 94,424,014 shares. The mentioned changes placed institutional holdings at 166,149,721 shares, according to the latest SEC report filing. CANO stock had 35 new institutional investments in for a total of 5,712,514 shares, while 33 institutional investors sold positions of 16,072,397 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here